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Abstract  
 
The reversible O-linked attachment of single β-D-N-acetylglucosamine (GlcNAc) 
moieties to serine/threonine residues in target proteins is a frequently occurring 
post-translational modification affecting the functionality of many cellular 
systems. In this report we present experimental evidences suggesting that the 
epidermal growth factor receptor (EGFR) is subjected to O-GlcNAcylation in 
human carcinoma epidermoid A431 and human lung carcinoma A549 cells. 
However, no signal was detected in human cervix adenocarcinoma HeLa cells 
or in mouse EGFR-T17 fibroblasts ectopically expressing the human EGFR. We 
detected a positive O-GlcNAcylation signal in immunoprecipitated EGFR by 
Western blot using two distinct specific anti-O-GlcNAc antibodies even after N-
deglycosylation of the receptor using peptide-N-glycosidase F (PNGase F). 
Conversely, the presence of EGFR was detected by Western blot using an anti-
EGFR antibody in the immunocomplex of O-GlcNAcylated proteins 
immunoprecipitated with an anti-O-GlcNAc antibody. These signals were 
enhanced when the O-linked β-N-acetylglucosaminidase (OGA) inhibitor 
Thiamet G was added to prevent the deglycosylation of the GlcNAc moiety(ies). 
Moreover, we also detected a positive signal in the immunoprecipitated and N-
deglycosylated EGFR using PNGase F, and tunicamycin when the cells were 
metabolically labeled with azido-GlcNAc (GlcNAz), biotinylated and probed with 
streptavidin-labeled peroxidase. Finally, EGFR and OGT co-immunoprecipitate, 
and incubation of immunoprecipitated EGFR with immunoprecipitated O-linked 
β-N-acetylglucosamine transferase (OGT) in the presence of uridine 5´-
diphospho-N-acetylglucosamine (UDP-GlcNAc) resulted in a significant 
enhancement of the EGFR O-GlcNAcylation signal as detected by Western blot 
using an anti-O-GlcNAc antibody. We conclude that the human EGFR is 
subjected to O-GlcNAcylation in the A431 and A549 tumor cell lines. 
 
Introduction 
 
Protein O-GlcNAcylation is a post-translational modification first identified 
in lymphocyte proteins1, consisting in the reversible O-linked attachment of 
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single β-D-N-acetylglucosamine (GlcNAc) moieties to serine/threonine residues 
in target proteins; thus modifying their enzymatic activity, intracellular location, 
turnover, and/or other functional roles2. Since those early days, literally 
hundreds of additional cytosolic, nuclear and mitochondrial proteins have been 
identified to be O-GlcNAcylated, and it is likely that this number would be 
growing in the future. Altered O-GlcNAcylation has been proposed to contribute 
to the etiology of many illnesses such type-2 diabetes3-6, cardiovascular 
ailments3, 7, neurodegeneration as in Alzheimer’s disease3, 4, 8, 9 and cancer4, 10-
13. 
 
The enzymes O-linked β-N-acetylglucosamine transferase (OGT)14 and 
O-linked β-N-acetylglucosaminidase (OGA)15 catalyze the reversible O-
GlcNAcylation of proteins, the first one doing the glycosylation and the latter 
one the deglycosylation. Several OGT isoforms are present in the cell, more 
relevantly a canonical long form localized in the nucleus and cytosol (ncOGT), 
another one a bit shorter localized in the inner mitochondrial membrane 
(mOGT), and a third one, the shortest of them (sOGT), also localized in the 
nucleus and cytosol14. In addition, an atypical epidermal growth factor (EGF)-
like-repeat domain specific OGT (EOGT) able to O-GlcNAcylate the side chain 
of Ser/Thr at the extracellular segment of different proteins, including Dumpy in 
Drosophila and the Notch receptor in mouse, has been identified16-18. 
 
Protein O-GlcNAcylation appears to be at the same footing than protein 
phosphorylation in terms of importance in regulating signal transduction events; 
and indeed it exists a complex crosstalk between both events taking place 
either at the same site, or at distinct adjacent, proximal or distant sites, 
competing or facilitating each other in the choreographic orchestration of 
signaling fluxes regulating multiple pathways implicated in the physiology of the 
cell, such as: metabolic control, stress response, epigenetic modification, gene 
transcription, translation of proteins, protein turnover, differentiation, apoptosis 
and cell cycle control to mention a few4, 19-22. Moreover, O-GlcNAcylation of 
some proteins can also affect its phosphorylation at tyrosine residues, as it is 
the case of prohibitin23. 
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Among the OGT substrates a large set of serine/threonine- and tyrosine-
kinases were identified, amounting to forty-two of a total of 152 candidate 
kinases tested in a particular study24. Moreover, and of interest to the present 
study, the insulin receptor, a relevant member of the receptor tyrosine kinase 
(RTK) superfamily, is also subjected to O-GlcNAcylation, process that 
modulates the functionality of the receptor and down-stream signaling 
pathways25. However, little information is available on O-GlcNAcylation of other 
RTKs. 
 
The epidermal growth factor receptor (EGFR) is an RTK implicated in the 
control of cell proliferation, differentiation, cell survival, programmed cell death 
and cell migration processes, and this receptor is frequently overexpressed or 
mutated in many solid tumors thus contributing to cancerogenesis26, 27. In an 
early report, using high throughput proteomic analysis, labeling proteins of 
Drosophila melanogaster with the GlcNAc analogue azido-GlcNAc, the EGFR 
type III was identified, suggesting that it was susceptible to undergo O-
GlcNAcylation28. Thereafter, in an entirely in silico study it was proposed that 
the human EGFR could be subjected to O-GlcNAcylation at Thr654 and 
Ser1046/Ser104729, phosphorylation sites of protein kinase C (PKC)30 and 
calmodulin-dependent protein kinase II (CaMK-II)31, respectively. However, 
experimental evidence for this proposed post-translational modification of 
human EGFR is lacking up to day. In this report we shall provide for the first 
time proof that indeed the human EGFR could be subjected to O-GlcNAcylation 
in two distinct tumor cell lines, discuss the uncertainties pending to be resolved 
on the occurrence of this post-translational modification in the EGFR, and 
suggest potential physiological consequence of this event for the functionality of 
the receptor. 
 
Material and Methods 
Reagents and antibodies 
Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP), O-(2-
acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenyl carbamate 
(PUGNAc), 3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-
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(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol (Thiamet G), tunicamycin, 
UDP-GlcNAc (sodium salt), anti-mouse IgG (Fc specific) horseradish 
peroxidase (HRP)-conjugated secondary antibody, mouse monoclonal anti-
tubulin-α (DM1A) antibody and purified mouse IgG (technical grade) were 
obtained from Sigma-Aldrich Co. (St. Louis, MO). Mouse monoclonal anti-
phosphotyrosine antibody (4G10, isotype IgG2bκ) and rabbit monoclonal anti-
EGFR (E235) antibody (recognizing the C-terminal domain of EGFR) were 
obtained from Millipore (Billerica, MA). Rabbit monoclonal anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (14C10) antibody was obtained from 
Cell Signalling. Anti-rabbit IgG HRP-linked secondary antibody, streptavidin 
peroxidase-conjugated tetraacetylated N-azidoacetylglucosamine (GlcNAz) and 
Click-iT®-protein reaction buffer kit were obtained from Invitrogen (Eugene, 
OR). The classic magnetic IP/Co-IP kit, the O-GlcNAc Western blot detection kit 
containing the mouse monoclonal anti-O-GlcNAc monoclonal antibody 
(CTD110.6) and goat anti-mouse IgM (µ heavy chain) HRP-conjugated 
secondary antibody were obtained from Thermo Scientific-Pierce (Rockford, IL). 
The O-GlcNAc antibody (RL2) was obtained from Novus Biologicals (Littleton, 
USA). Anti-OGT antibody (ab50271) was obtained from Abcam (Cambridge, 
UK) and peptide-N-glycosidase F (PNGase F) (from Flavobacterium 
meningosepticum) was obtained from New England BioLabs (Herts, UK). 
 
Cell culture 
Human carcinoma epidermoid A431 cells, human lung carcinoma A549 
cells, human cervix adenocarcinoma HeLa cells, and mouse EGFR-T17 
fibroblast stably transfected with the human EGFR were routinely cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % (v/v) 
fetal bovine serum (FBS), 2 mM L-glutamine and 40 µg/ml gentamicin at 37 ºC 
in a humidified air atmosphere containing 5 % CO2. 
 
O-GlcNAc detection in EGFR 
EGFR was immunoprecipitated from the different cell lines using the 
Pierce Classic Magnetic IP/Co-IP kit following the manufacturer instructions. 
Briefly, the cell  lysates (1-2 mg proteins) were incubated with anti-EGFR 
antibody (1:500 dilution) overnight at 4 ºC. The lysate containing the antigen-
Page 5 of 26 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
09
 Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
by
 In
sti
tu
to
 d
e I
nv
es
t B
io
m
ed
ic
as
 A
lb
er
to
 S
ol
s (
IIB
M
) o
n 0
9/0
6/2
01
5 1
6:2
4:5
4. 
View Article Online
DOI: 10.1039/C5OB00443H
 6 
antibody complex was mixed with the magnetic beads and incubated for 1 hour 
at room temperature. The beads were extensively washed and the EGFR was 
released with the low pH (pH-2) elution buffer, resolved in polyacrylamide gel 
electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) and 
subjected to Western blot using appropriate anti-O-GlcNAc antibodies (RL2 or 
CTD110.6). Conversely, a lysate of A431 cells (1-2 mg proteins) was incubated 
as above with an anti-O-GlcNAc antibody (RL2) and the immunoprecipitated O-
GlcNAcylated proteins were resolved in SDS-PAGE and subjected to Western 
blot using and anti-EGFR antibody. 
 
EGFR and OGT co-immunoprecipitation 
Co-immunoprecipitation of EGFR and OGT from A431 cells (2 mg 
protein) was performed using the PierceTM Classic Magnetic IP/Co-IP kit and 
either anti-EGFR or anti-OGT antibodies following the manufacture instructions. 
The samples were processed for SDS-PAGE and Western blot using both anti-
EGFR and anti-OGT antibodies to detect co-immunoprecipitation of the two 
proteins. 
 
In vitro EGFR O-GlcNAcylation 
Immunoprecipitated EGFR was used as substrate for in vitro O-
GlcNAcylation assay using immunoprecipitated OGT from A431 cells. The O-
GlcNAcylation reaction took place in a buffer containing 50 mM 
tris(hydroxymethyl)aminomethane (Tris)-HCl (pH 7.5), 1 mM dithiotreitol, 12.5 
mM MgCl2 and 1 mM UDP-GlcNAc, and incubated for 2.5 h at 30 ºC. The 
reaction was stopped by adding Laemmli buffer and boiled for 10 min at 100 ºC, 
resolved in SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) 
membrane, and probed with an anti-O-GlcNAc antibody (RL2). 
 
Metabolic protein labeling with GlcNAz 
A431 cells were seeded in 150 cm2 petri dishes and when ~ 70 % 
confluence was attained 40 µM GlcNAz was added and incubated for 72 h. The 
cells were lysed in а buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1 mM ethylenediaminetetraacetic acid (EDTA), 1 % (v/v) nonyl 
phenoxypolyethoxylethanol (NP-40) and 5 % (v/v) glycerol supplemented with 
Page 6 of 26Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
09
 Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
by
 In
sti
tu
to
 d
e I
nv
es
t B
io
m
ed
ic
as
 A
lb
er
to
 S
ol
s (
IIB
M
) o
n 0
9/0
6/2
01
5 1
6:2
4:5
4. 
View Article Online
DOI: 10.1039/C5OB00443H
 7 
20 µM PUGNAc to prevent deglycosylation and a cocktail of protease inhibitors: 
0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), 0.4 µM aprotinin, 
25 µM bestatin, 7.5 µM [1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-
leucyl]amino]-4-guanidinobutane] (E-64), 10 µM leupeptin, 5 µM pepstatin A, 
and freshly prepared 0.6 mM phenylmethylsulfonyl fluoride (PMSF). The lysate 
was centrifuged at 16,000 g for 10 min and the supernatant used for EGFR 
immunoprecipitation. Biotinylation of the GlcNAz-labeled proteins was 
performed using the Click-iT®-Protein Reaction Buffer kit following the 
manufacturer’s instructions, the samples were subjected to SDS-PAGE, the 
proteins transferred to PVDF and overlaid with streptavidin-HRP (1:10,000 
dilution). 
 
N-deglycosylation of the EGFR 
The immunoprecipitated EGFR was first denatured in a buffer containing 
0.5 % (w/v) SDS and 40 mM dithiothreitol and boiled for 10 min at 100 °C. 
Thereafter, 10 % (v/v) NP-40, 50 mM sodium phosphate (pH 7.5) and 1,000 
units of PNGase F were added, and the mixture was incubated for 2 h at 37 ºC. 
One unit of PNGase F is defined as the amount of enzyme required to remove 
> 95 % of the carbohydrates from 10 µg of denatured RNase B in 1 hour at 37 
°C. The reaction was stopped by the addition of Laemmli buffer and boiled for 
10 min at 100 ºC, resolved in SDS-PAGE, transferred to a PVDF membrane 
and probed with anti-O-GlcNAc antibodies (RL2 or CTD110.6). When 
tunicamycin was used as a deglycosylation agent A431 cells were cultured in 
complete DMEM supplemented with 1 µg/ml tunicamycin overnight where only 
newly synthetized EGFR molecules are expected to be fully N-deglycosylated. 
Higher concentrations of tunicamycin to attain more N-deglycosylated EGFR 
molecules was not possible as more drastic treatments result in extensive cell 
death. 
 
Effect of OGT and OGA inhibitors on EGFR O-GlcNAcylation in living cells  
A431 cells were grown to confluence in 6-well culture dishes containing 2 
ml of DMEM supplemented with 10 % (v/v) FBS overnight in the absence and 
presence of the OGT inhibitor BADGP (2 mM), or the OGA inhibitor Thiamet G 
(20 µM). Thereafter, the EGFR was immunoprecipitated from a cell lysate using 
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an anti-EGFR antibody and the immunocomplex was processed by Western 
blot using an anti-O-GlcNAc antibody (RL2). Alternatively, O-GlcNAcylated 
proteins were immunoprecipitated using an anti-O-GlcNAc antibody (RL2) from 
a cell lysate and the immunocomplex was processed by Western blot using an 
anti-EGFR antibody. The effect of 2 mM BADGP and increasing concentrations 
(0.5-20 µM) of Thiamet G was also tested on total proteins O-GlcNAcylation 
level from an A431 cell lysate as positive control. 
 
Polyacrylamide gel electrophoresis and Western blot 
Proteins were separated by SDS-PAGE in a 5-20 % (w/v) linear gradient 
slab gel of polyacrylamide and 0.1 (w/v) sodium dodecyl sulfate (pH 8.3) at 6-10 
mA overnight32. The proteins were electrotransferred from the gels to a PVDF 
membrane for 2 h at 300 mA in a medium containing 48 mM Tris-base, 36.6 
mM L-glycine, 0.04 % (w/v) SDS and 20 % (v/v) methanol. The proteins were 
fixed with 0.2 % (v/v) glutaraldehyde in 25 mM Tris-HCl (pH 8), 150 mM NaCl 
and 2.7 mM KCl (TNK buffer) for 45 min, and transiently stained with Fast 
Green to ascertain the regularity of the transfer procedure. The PVDF 
membranes were blocked with 5 % (w/v) bovine serum albumin or 5 % (w/v) fat-
free powdered milk following the instructions of the antibodies' manufacturers in 
0.1 % (w/v) Tween-20, 100 mM Tris-HCl (pH 8.8), 500 mM NaCl and 0.25 mM 
KCl (T-TBS buffer), and probed overnight at 4°C using a 1/2000 dilution of the 
corresponding primary antibody, and for 1 h at room temperature using a 
1/5000 dilution of the appropriate secondary anti-IgG or anti-IgM antibodies 
coupled to HRP. The bands were visualized upon development with an 
enhanced chemiluminescence kit, following instructions from the manufacturer, 
and exposure of x-ray films for appropriate periods of time. The intensity of the 
bands was quantified using the ImageJ 1.46r program (National Institutes of 
Health, USA). 
 
Statistical analysis 
The two-tailed paired Student’s t test was performed using the Microsoft 
Excel (Microsoft Co., Redmon, WA) software program. Data were expressed as 
the mean ± SEM and differences were considered significant at p ≤ 0.05. 
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Results 
 
Protein O-GlcNAcylation in A431 tumor cells 
We first tested for the presence of O-GlcNAcylated proteins in whole cell 
lysates of A431 tumor cells by Western using two distinct (CTD110.6 and RL2) 
anti-O-GlcNAc specific antibodies (Fig. 1A). The presence of multiple strongly 
labeled bands of O-GlcNAcylated proteins in a range of > 250 kDa to < 50 kDa 
were detected presenting a similar distribution pattern when both antibodies 
were used. Fainter bands were also detected in overexposed films (not shown). 
When cells were treated with Thiamet G, a highly specific OGA inhibitor to 
prevent O-GlcNAc deglycosylation33, a significant two-fold increase in protein 
O-GlcNAcylation level was detected as expected (Figs. 1B-1D). Moreover, we 
also tested BADGP, a general O-glycosylation inhibitor not specific for O-
GlcNAcylation but that also inhibits this process34-37, and a small but significant 
decrease in protein O-GlcNAcylation was detected (Figs. 1B, 1C). 
 
EGFR O-GlcNAcylation detected by immunoblots 
 To determine whether the EGFR from A431 tumor cells undergoes O-
GlcNAcylation we treated the immunoprecipitated receptor in the absence and 
presence of PNGase F to remove N-glycans, and tested for O-GlcNAcylation 
using the same two distinct anti-O-GlcNAc antibodies mentioned above (Figs. 
2A, 2B). The results show that in both instances, not only the 170 kDa native 
EGFR, but most significantly and in greater extent the ~150 kDa N-
deglycosylated receptor, yielded positive signals. To ascertain the specificity of 
the CTD110.6 anti-O-GlcNAc antibody, we competed its reactivity using an 
excess (20 mM) of free GlcNAc in the incubation medium (Fig. 2C). 
 
Furthermore, we performed the experiment in reverse, 
immunoprecipitating first O-GlcNAcylated proteins from an A431 cell lysate and 
detecting the presence of EGFR in the immunoprecipitate (Fig. 2D). When the 
cells were previously treated with the OGA inhibitor Thiamet G, the EGFR 
signal was slightly increased, although not significant decrease was detected 
when cells were treated with the O-glycosylation inhibitor BADGP (Fig. 2D). In 
agreement with this, we also demonstrated that when A431 cells were treated 
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with Thiamet G the O-GlcNAcylation level of the immunoprecipitated native 170 
kDa EGFR also increased, although little if any increment was detected in the 
~150 kDa N-glycans-free EGFR band (Figs. 3A, 3B). 
 
EGFR O-GlcNAcylation detected by metabolic labeling with azido-GlcNAc 
 We next tried to detect O-GlcNAcylation of the EGFR by metabolically 
labeling cellular glycans in proteins from A431 cells with azido-GlcNAc. Fig. 4A 
shows that after immunoprecipitation both the native 170 kDa EGFR and its 
~150 kDa N-glycans-free form, obtained after PNGase F treatment, yielded a 
positive signal following biotinylation and overlay by streptavidin-HRP. This was 
observed in basal conditions and after EGF addition. The extent of the signal 
was lower in EGF-treated cells but this most likely represents degradation of the 
receptor after ligand-induced internalization, as this process has been amply 
documented 38, 39, and we further document this degradation in Figs. 4B, 4C. 
We also treated A431 cells with tunicamycin to obtain EGFR devoid of N-
glycans by a different method. Fig. 4D shows that the native 170 kDa receptor 
and its ~150 kDa N-deglycosylated form both were metabolically labeled with 
azido-GlcNAc, even after further treating the immunoprecipitate EGFR with 
PNGase F. 
 
EGFR O-GlcNAcylation in different cell lines 
 We tested different human tumor cell lines, with distinct levels of EGFR 
expression, and a mouse fibroblast stably transfected and overexpressing the 
human EGFR for O-GlcNAcylation of the receptor. Fig. 5 shows a positive 
signal in human carcinoma epidermoid A431 cells, which were used as positive 
control. Also, a positive signal was detected in human lung carcinoma A549 
cells. The double band observed in A549 cells may represent the presence of 
an unrelated O-GlcNAcylated protein associated to the EGFR and/or another 
ErbB receptor forming heterodimers with the EGFR. However, no O-
GlcNAcylation of the EGFR was detected in human cervix adenocarcinoma 
HeLa cells or in the recombinant human EGFR ectopically expressed in mouse 
EGFR-T17 fibroblasts. 
 
In vitro EGFR O-GlcNAcylation 
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 To attain a further proof that the EGFR could be O-GlcNAcylated, we 
assayed in vitro the enzymatic activity of immunoprecipitated OGT from A431 
cells using as substrate the immunoprecipitated EGFR from the same origin. 
We first show that EGFR and OGT can be co-immunoprecipitated (Fig. 6A), 
suggesting that the two proteins interact in living cells. Our results on the in vitro 
enzymatic assays show a significant increment in the O-GlcNAcylation level of 
the EGFR as detected by Western blot using an anti-O-GlcNAc antibody (RL2) 
(Figs. 6B, 6C). Given the fact that the immunoprecipitated EGFR was already 
O-GlcNAcylated before starting the reaction catalyzed by OGT, this increment 
only reached ~1.8 ± 0.2 fold. This, nevertheless, strongly suggests that the 
EGFR undergoes this post-translational modification. 
 
Discussion 
 
 Overall our results show for the first time that human EGFR could be 
subjected to O-GlcNAcylation, as it is the case for the insulin receptor25. We 
detected EGFR O-GlcNacylation in two distinct human tumor cell lines, A431 
and A549 cells. The first one, derived from a tumor of epidermic origin, and the 
second one from a lung epithelial tumor. In contrast, no signal was detected in 
HeLa cells that are derived from a cervical adenocarcinoma, and therefore are 
from glandular origin. This demonstrates that EGFR O-GlcNacylation may not 
occur in all tumor cells as this process could depend of its tissular and/or organ 
origin. Moreover, the absence EGFR O-GlcNacylation signal in EGFR-T17 
fibroblasts suggests that this post-translational modification may not be 
operative in a non-physiological setting where a recombinant human EGFR is 
artificially expressed in cells from another species. 
 
This post-translational modification is expected to take place in the 
cytosolic region of the EGFR. Nevertheless, it is noticeable that when the 
immunoprecipitated EGFR was treated with PNGase F the immunoreactivity of 
the ~150 kDa N-deglycosylated receptor to the two anti-O-GlcNAc antibodies 
used increased as compared with the native 170 kDa EGFR. This suggests that 
removal of N-glycans from the extracellular region of the EGFR could facilitate 
the exposure of occluded GlcNAc moieties linked to complex O-glycans, not 
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related to O-GlcNAcylation events but that could be non-specifically recognized 
by the two anti-O-GlcNAc antibodies used in this study. In fact, the presence of 
O-glycans in the extracellular region of the EGFR has been described40. 
Alternatively, the increased immunoreactivity of the anti-O-GlcNAc antibodies 
after the removal of the N-glycans by PNGase F, could be also related to the 
extracellular O-GlcNAcylation of the receptor, modification driven by EOGT16-18. 
We identified in the extracellular region of the EGFR three sites 
(215CAQQCSGRC223, 236CAAGCTGPRE245 and 506CHALCSPEGC515) that 
contain key amino acids (cysteine, glycine and serine/threonine) that are also 
present in the EGF-like domain consensus sequence CXXGXS/TGXXC 
recognized by EOGT41. These sites are in the S1 and S2 cysteine-rich regions 
of the receptor, and the cysteine residues located in the proposed sequences 
are involved in the formation of disulfide bridges42. Moreover, the strict 
specificity of some of the anti-O-GlcNAc antibodies has been questioned, as for 
example the CTD110.6 antibody that also recognizes terminal β-GlcNac in 
complex N-glycans43. 
 
PNGase F is extensively used to remove N-glycans from glycoproteins44, 
but this endoglycosidase is unable to work if a α1-3 bond links fucose to the 
innermost GlcNAc attached to asparagine45. Although α1-3-linked fucose to the 
innermost GlcNAc residues attached to asparagine is common in plant and 
insect glycoproteins, it appears to be absent in mammalian cells, where α1-6-
linked fucosylation of core GlcNAc catalyzed by fucosyl transferase 8 (FUT8) 
appears to be the norm46. Nevertheless, to eliminate the possible existence of 
an unrecognized aberrant α1-3-linked fucosylation of the innermost GlcNAc 
attached to asparagine in tumor cells we used tunicamycin treatment. Our 
results with tunicamycin also supports absence of α1-3-linked fucosylation of 
core GlcNAc in the EGFR from A431 cells, as GlcNAz labeling was clearly 
detected in the  ~150 kDa N-deglycosylated EGFR. 
 
The suggestion that the EGFR could be subjected to O-GlcNAcylation at 
Thr654 and Ser1046/Ser1047 based on in silico modeling as proposed by 
Kaleem et al.29 is pending experimental confirmation, as many predicting 
Page 12 of 26Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
09
 Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
by
 In
sti
tu
to
 d
e I
nv
es
t B
io
m
ed
ic
as
 A
lb
er
to
 S
ol
s (
IIB
M
) o
n 0
9/0
6/2
01
5 1
6:2
4:5
4. 
View Article Online
DOI: 10.1039/C5OB00443H
 13
software programs are prone to both false-positive and false-negative 
predictions47. We attempted some experiments using mass spectrometry (MS) 
to detect EGFR O-GlcNAcylation. However, the lack of detected peptides 
corresponding to the cytosolic juxtamembrane region of the EGFR, where 
Thr654 is located, prevented attaining meaningful results. We believe that the 
identification in human EGFR of O-linked GlcNAc moiety/ies and the specific 
Ser and/or Thr residue(s) where it may be attached using a suitable MS method 
or another technology could be, if positive, the ultimate proof of EGFR O-
GlcNAcylation. 
 
If Thr654 were to be confirmed as an O-GlcNAcylation site in EGFR, an 
interesting subject would be to elucidate the possible tripartite crosstalk that 
may be established between the phosphorylation of this site by PKC30, the 
binding of calmodulin (CaM) to the cytosolic juxtamembrane region of the 
receptor where the Thr654 residue is located48, and the O-GlcNAcylation event. 
We have demonstrated that phosphorylation of Thr654 by PKC prevents CaM 
binding to this region, and conversely binding of CaM prevents Thr654 
phosphorylation by PKC48. Thus, it is expected that if Thr654 were targeted by 
OGT a more complex functional picture could emerge by the presence of this 
O-GlcNAcylated residue. Particularly, since phosphorylation of Thr654 appears 
to inhibit ligand-dependent EGFR activation and maintaining the receptor in 
stand-by at the plasma membrane slowing its internalization49, and CaM binding 
appears to contribute to ligand-dependent EGFR activation in living cells50. 
 
Finally, another important issue to be studied in future work would be to 
establish the potential impact that O-GlcNAcylation may have on EGFR 
functionality, particularly its putative action on ligand-dependent activation, 
receptor downregulation, membrane location, nuclear translocation, 
internalization, intracellular traffic and/or degradation via the lysosomal and/or 
the ubiquitin-proteasome pathways. Interestingly, it is known that the EGFR can 
be located in non-caveloar lipid rafts51, as also occurs with a fraction of the O-
GlcNAc transferase when cells are stimulated with insulin52. This suggests that 
the co-localization of OGT and the EGFR at the same membrane micro-
domains could facilitate the O-GlcNAcylation of the receptor. How these events 
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may affect important EGFR-mediated cellular functions, such as cell 
proliferation, differentiation, cell survival, programmed cell death and/or cell 
migration processes warrant also special attention, as well as how this post-
translational modification of the EGFR may goes awry in pathological conditions 
such as cancer. 
 
Conclusion 
 
We conclude that the accumulated experimental evidences presented in 
this report using different techniques strongly suggest that the human EGFR 
from A431 and A549 tumor cells is subjected to O-GlcNAcylation. Nevertheless, 
the identification of the serine and/or threonine residue(s) implicated in this 
post-translational modification, and the role that this process may have in the 
functionality of the EGFR and the physiology of the cell, particularly EGFR-
mediated cell proliferation, survival, differentiation, and/or cell motility, are 
important issues to be study in future work. Moreover, since altered signaling 
processes is known to occur in tumor cells, it would also be of great interest to 
determine whether this particular O-GlcNAcylation detected in the EGFR is an 
aberrant process happening only in some cancerous cells, or by contrast is a 
physiological process also occurring in the receptor of non-transformed cells. 
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LEGENDS TO THE FIGURES 
 
Figure 1. Effects of OGT and OGA inhibitors on protein O-GlcNAcylation. 
(A) A total cell extract of A431 cells was processed by SDS-PAGE and Western 
blots (WB) as described in Materials and Methods and probed with the anti-O-
GlcNAc antibodies CTD110.6 and RL2 as indicated. (B) A431 cells were 
incubated overnight in the absence (None) and presence of 20 µM Thiamet G 
or 2 mM BADGP as indicated. Whole cell lysates were processed by SDS-
PAGE and Western blots (WB) as described in Materials and Methods and 
probed with an anti-O-GlcNAc antibody (RL2). The PVDF membranes were 
stripped and reprobed with an anti-GAPDH antibody as loading control. (C) The 
plot presents the mean ± SEM (n = 4) protein O-GlcNAcylation from a set of 
experiments similar to the one shown in A measuring the densitometry of the O-
GlcNAcylated bands corrected by loading as determined by protein staining with 
Fast Green. (*) p < 0.05 as determined by the Student’s t test. (D) The plot 
presents the mean ± SEM (n = 3) protein O-GlcNAcylation from a set of 
experiments similar to the one shown in A but using the indicated 
concentrations of Thiamet G and measuring the densitometry of the O-
GlcNAcylated bands corrected by loading as determined by protein staining with 
Fast Green. 
 
Figure 2. Detection of O-GlcNAcylation signal in EGFR by 
immunoprecipitation and Western blot. (A, B) The EGFR was 
immunoprecipitated (IP) from a cell extract of A431 cells using an anti-EGFR 
antibody and the immunocomplex was incubated in the absence (-) and 
presence (+) of PNGase F to remove N-glycans. The samples were 
immunoblotted (WB) with the anti-O-GlcNAc antibodies CTD110.6 (A) and RL2 
(B) as indicated. The PVDF membranes were stripped and reprobed with an 
anti-EGFR antibody as loading controls. Mock IP were performed using a non-
relevant IgG as negative controls. Upper and lower arrowheads point to the 
native and N-deglycosylated EGFR, respectively. (C) Immunoprecipitated (IP) 
EGFR, a mock immunoprecipitation using a non-relevant immunoglobulin G 
fraction (Mock IP) and an A431 total cell extract were immunoblotted (WB) 
using an anti-O-GlcNAc antibody (CTD110.6) in the absence (-) and presence 
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(+) of an excess (20 mM) of free GlcNAc as indicated to test the specificity of 
the antibody. The films were overexposed to ascertain absence of signal in the 
control with 20 mM GlcNAc. Black arrowhead points to O-GlcNAcylated EGFR 
and gray arrowheads point to the heavy and light chains of IgG. The small lower 
inset shows protein staining with Fast Green as loading control. The arrowhead 
points to the EGFR. (D) A431 cells were incubated overnight in the absence 
(None) and presence of 20 µM Thiamet G or 2 mM BADGP as indicated. The 
samples were immunoprecipitated (IP) using an anti-O-GlcNAc antibody (RL2) 
and the immunocomplex processed by SDS-PAGE and Western blots (WB) as 
described in Materials and Methods and probed with anti-EGFR and anti-O-
GlcNAc (RL2) antibodies. The gray arrowheads point to the heavy and light 
chains of IgG. The heavy light chain of IgG was also stained with Fast Green as 
loading control. Mock IP was performed using a non-relevant IgG as negative 
control. 
 
Figure 3. Effects of OGT and OGA inhibitors on EGFR O-GlcNAcylation 
signal. (A) A431 cells were incubated overnight in the absence (None) and 
presence of 20 µM Thiamet G or 2 mM BADGP as indicated. The samples were 
immunoprecipitated (IP) using an anti-EGFR antibody and the immunocomplex 
was incubated in the absence (-) and presence (+) of PNGase F to remove N-
glycans and processed by SDS-PAGE and Western blots (WB) as described in 
Materials and Methods and probed with an anti-O-GlcNAc antibody (RL2). The 
PVDF membrane was stripped and reprobed with an anti-EGFR antibody as 
loading control. Upper and lower arrowheads point to the native and N-
deglycosylated EGFR, respectively. (B) The plot presents the mean ± SEM (n = 
3) EGFR O-GlcNAcylation from a set of experiments similar to the one shown in 
A measuring the densitometry of the O-GlcNAcylated bands corrected by 
loading as determined by the total EGFR signal. (*) p < 0.05 as determined by 
the Student’s t test.  
 
Figure 4. Detection of O-GlcNAcylation signal in EGFR by 
immunoprecipitation and GlcNAz labeling. (A) Serum-starved A431 cells 
were treated overnight with 40 µM GlcNAz and incubated as indicated in the 
absence (-) and presence (+) of 10 nM EGF during 30 min. Thereafter, the 
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EGFR was immunoprecipitated (IP) and where indicated treated with PNGase F 
to remove N-glycans. The samples were subjected to biotinylation and overlaid 
with streptavidin-HRP to detect GlcNAz-labeled proteins as described in 
Materials and Methods. Immunoprecipitated EGFR from cells non-treated with 
GlcNAz (No GlcNAz) and a mock IP are shown as negative controls. Protein 
staining of the immunoprecipitated EGFR with Fast Green is shown as loading 
control. Duplicate samples of the immunoprecipitated EGFR were processed by 
Western blot using an anti-EGFR antibody are shown where indicated. Upper 
and lower black arrowheads point to the native and N-deglycosylated EGFR, 
respectively, and the gray arrowhead points to a partially degraded N-
deglycosylated EGFR. (B) Serum-starved A431 cells were treated in the 
absence (-) and presence (+) of 10 nM EGFR for 30 min. The reaction was 
arrested with 10 % (w/v) trichloroacetic acid, and the samples were processed 
for SDS-PAGE and immunoblot using an anti-phospho-tyrosine antibody to 
detect phosphorylated EGFR (P-EGFR) and an anti-EGFR antibody to detect 
total EGFR. GAPDH is shown as a loading control. (C) The plot presents the 
mean ± SEM (n = 3) of the densitometry of the EGFR/GAPDH signal ratio to 
control for possible loading differences. (**) p < 0.01 as determined by the 
Student’s t test. (D) A431 cells were treated overnight with 1 µg/ml tunicamycin, 
the EGFR was immunoprecipitated (IP) and where indicated treated with 
PNGase F to remove residual N-glycans. The samples were subjected to 
biotinylation and overlaid with streptavidin-HRP to detect GlcNAz-labeled 
proteins as described in Materials and Methods. Duplicate samples were 
probed with an anti-EGFR antibody. Immunoprecipitated EGFR from cells non-
treated with GlcNAz (No GlcNAz) and a mock IP are shown as negative 
controls. Upper and lower arrowheads point to the native and N-deglycosylated 
EGFR, respectively. 
 
Figure 5. O-GlcNAcylation of EGFR in different cell lines. A431, A549, HeLa 
and EGFR-T17 cells were incubated overnight in the presence of 20 µM 
Thiamet. The EGFR was immunoprecipitated (IP) using an anti-EGFR antibody 
and the immunocomplexes were processed by SDS-PAGE and immunoblot 
(WB) using anti-O-GlcNac (RL2) and anti-EGFR antibodies as described in 
Materials and Methods. A mock IP was performed using a non-relevant IgG as 
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negative control. 
 
Figure 6. Enhanced O-GlcNAcylation of EGFR upon in vitro reaction 
catalyzed by immunoprecipitated OGT. (A) OGT and EGFR were 
independently immunoprecipitated from A431 cells and the samples were 
processed by immunoblot (WB) using anti-OGT and anti-EGFR antibodies to 
test for co-immunoprecipitation of both proteins. Mock IP were performed using 
a non-relevant IgG as negative controls. (B) OGT and EGFR were 
independently immunoprecipitated from A431 cells. Thereafter, the 
immunoprecipitated EGFR was incubated in the absence (-) and presence (+) 
of immunoprecipitated OGT and the O-GlcNAcylation reaction was performed 
upon addition of UDP-GlcNAc as described in Materials and Methods. The 
samples were immunoblotted (WB) with an anti-O-GlcNAc antibody (RL2) as 
indicated. OGT and EGFR were detected by WB using anti-OGT and anti-
EGFR antibodies, respectively. (C) The plot presents the mean ± SEM EGFR 
O-GlcNAcylation in the absence (None) and presence of OGT from 3 
independent experiments similar to the one shown in B measuring the 
densitometry of the O-GlcNAcylated EGFR band corrected by loading as 
determined by protein staining with Fast Green. (*) p < 0.05 as determined by 
the Student’s t test. 
 
LEGEND TO THE GRAPH ABSTRACT 
 
The cartoon represents the EGFR at the plasma membrane where 
serine/threonine residues could be subjected to 
phosphorylation/dephosphorylation events by protein kinases (PK) and 
phospho-protein phosphatases (PPP) and to O-GlcNAcylation/deGlcNAcylation 
events by O-linked β-N-acetylglucosamine transferase (OGT) and O-linked β-N-
acetylglucosaminidase (OGA). 
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